Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells

• Published in: The Prostate Vol. 67; no. 10; pp. 1121 - 1131
• Main Authors: Morgenroth, Agnieszka, Cartellieri, Marc, Schmitz, Marc, Günes, Serap, Weigle, Bernd, Bachmann, Michael, Abken, Hinrich, Rieber, Ernst Peter, Temme, Achim
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.07.2007; Wiley-Liss
• Subjects: Animals; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - metabolism; Antigens, Neoplasm; Biological and medical sciences; Cell Line; Cell Line, Tumor; Chimera - genetics; Chimera - immunology; Chimera - metabolism; chimeric T-cell receptor; Genetic Engineering; GPI-Linked Proteins; Gynecology. Andrology. Obstetrics; Humans; immunotherapy; Immunotherapy - methods; Jurkat Cells; Male; Male genital diseases; Medical sciences; Membrane Glycoproteins - genetics; Membrane Glycoproteins - immunology; Membrane Glycoproteins - metabolism; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Neoplasm Proteins - genetics; Neoplasm Proteins - immunology; Neoplasm Proteins - metabolism; Nephrology. Urinary tract diseases; prostate carcinoma; Prostatic Neoplasms - immunology; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - therapy; PSCA; Receptors, Antigen, T-Cell - genetics; Receptors, Antigen, T-Cell - immunology; Receptors, Antigen, T-Cell - metabolism; T-Lymphocytes, Cytotoxic - cytology; T-Lymphocytes, Cytotoxic - metabolism; T-Lymphocytes, Cytotoxic - pathology; Transfection; Tumors; Tumors of the urinary system; Urinary tract. Prostate gland; Andrology; Prostate carcinoma; Prostate tumor; Nephrology; Urinary system disease; T cell receptor; Prostate disease; Targeting; PSCA; Gynecology; Tumoral marker; Malignant tumor; Chimeric receptor; Treatment; Immunotherapy; chimeric T-cell receptor; T-Lymphocyte; Prostate stem cell antigen; Genetics; Male genital diseases; Prostate cancer; Tumor cell
• ISSN: 0270-4137; 1097-0045
• DOI: 10.1002/pros.20608

BACKGROUND Curative therapeutic options for minimal residual disease or advanced tumor stages in prostate cancer (PCa) are still missing. Adoptive transfer of cytotoxic T‐cells that have been polyclonally rendered tumor‐specific by genetic engineering appears to be a promising immunotherapeutic strategy. Among the numerous prostate tissue/tumor antigens identified during the last years, the “prostate stem cell antigen” (PSCA) is an attractive immunotherapeutic target. It is broadly expressed on the surface of primary PCa cells as well as on PCa metastases. METHODS To generate a chimeric T‐cell receptor (TCR) recognizing PSCA, a monoclonal anti‐PSCA antibody was raised and a single‐chain fragment (scFv) was prepared. The resulting anti‐PSCA scFv 7F5 was fused to the β2 constant region derived from the β‐chain of a TCR and to the CD3ζ‐signaling domain. RESULTS The chimeric α‐PSCA‐β2/CD3ζ‐TCR, expressed in Jurkat cells, was phosphorylated in the ITAMs of the CD3‐zeta chain upon cross‐linking by insolublized PSCA. When transduced into a mouse cytotoxic T‐cell line, the chimeric receptor specifically activated cytotoxicity against PSCA‐positive tumor cells. CONCLUSIONS We developed a functional chimeric TCR against PSCA for treatment of PCa. The chimeric α‐PSCA‐β2/CD3ζ‐TCR might now be used for arming human cytotoxic T‐cells for further studies towards a clinical treatment of PCa. Prostate 67: 1121–1131, 2007. © 2007 Wiley‐Liss, Inc.